---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Phase of product development"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Phase of product development. Topics: Regulatory status: Submission planned; BLA planned on the basis of the phase 3 CAPTIVATE trial, with Part B top-line results expected by the end of 2028; Investigational status; Single pivotal phase 3 trial announced, November 2024; Phase 3 CAPTIVATE trial initiated, February 2025; 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Submission planned; BLA planned on the basis of the phase 3 CAPTIVATE trial, with Part B top-line results expected by the end of 2028

> “Top-line results from all participants completing Part A of this trial are expected by the end of 2027, and top-line results from Part B of this trial are expected by the end of 2028. We believe that this single pivotal trial will support a Biologics License Application”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Top-line results from all participants completing Part A are expected by YE’27, and top-line results from Part B are expected by YE’28.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

> “Single pivotal two-part, randomized withdrawal, double-blind, placebo- controlled trial designed to support BLA in adult patients with CIDP”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Investigational status

> “Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-2.1.1-4"></a>

### Single pivotal phase 3 trial announced, November 2024

> “We believe this single, two-part, pivotal Phase 3 trial will support BLA filing in adult patients with CIDP and we anticipate initiating the trial by year-end 2024,”
> “Dianthus plans to initiate a single, two-part, randomized withdrawal Phase 3 trial of DNTH103 in CIDP by YE’24.”

Source: [Dianthus Therapeutics (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/dnth-ex99_1.htm)

<a id="topic-2.1.1-5"></a>

### Phase 3 CAPTIVATE trial initiated, February 2025

> “We are excited to have initiated our pivotal Phase 3 CAPTIVATE trial in CIDP, which is on track for an interim responder analysis in 2H’26, along with top-line results from our Phase 2 trial in MMN.”

Source: [Dianthus Therapeutics (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/dnth-ex99_1.htm)

> “Study Start (Actual) 2025-02-10”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.1-6"></a>

### Interim responder analysis: early GO decision, March 2026

> “This GO decision was reached early, after 20 confirmed responders were achieved with less than 40 planned participants completing Part A of the trial.”
> “The GO decision was confirmed by an independent DSMB review.”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

<a id="topic-2.1.1-7"></a>

### Trial resizing and removal of the 600 mg arm from Part B

> “engage with regulators to remove the claseprubart 600mg/4mL S.C. Q2W arm from Part B; and enroll up to 256 patients (previously up to 480) in Part A to randomize 128 patients in Part B (previously 192).”

Source: [Dianthus Therapeutics Form 10-Q (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000022/dnth-20260331.htm)

> “In November 2026, we announced that the CAPTIVATE trial is now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-2.1.1-8"></a>

### FDA written feedback on antinuclear antibody screening and drug-induced lupus, March 2026

> “Removal of anti-nuclear antibodies ("ANAs") as a screening criteria, a common reason for screen failure across all three claseprubart programs”
> “Removal of routine ANA testing during claseprubart clinical trials”
> “Reclassification of the hypothetical risk of systemic lupus erythematosus ("SLE") to drug-induced lupus ("DIL")”
> “In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials.”

Source: [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)

<a id="topic-2.1.1-9"></a>

### Orphan drug, fast track, or breakthrough therapy designation for CIDP

No evidence found.

<a id="topic-2.1.1-10"></a>

### Other indications in development

> “Dianthus is building a neuromuscular franchise with claseprubart and expects to report top-line results from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in December ’26, report top-line results from the Phase 3 CAPTIVATE trial Part A in CIDP by YE’27 and from Part B by YE’28, and report top-line results from the Phase 3 EMERGE trial in generalized Myasthenia Gravis in 2H’28.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
